Personalis (NASDAQ:PSNL) Price Target Raised to $11.00 at HC Wainwright

Personalis (NASDAQ:PSNL - Get Free Report) had its price objective increased by research analysts at HC Wainwright from $9.00 to $11.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 91.30% from the company's current price.

Separately, Needham & Company LLC reissued a "buy" rating and set a $7.25 target price on shares of Personalis in a research report on Friday.

Personalis Stock Performance

Shares of NASDAQ:PSNL traded up $0.49 during trading hours on Friday, reaching $5.75. The stock had a trading volume of 8,026,276 shares, compared to its average volume of 766,251. The stock has a market capitalization of $406.23 million, a price-to-earnings ratio of -3.42 and a beta of 1.88. The firm's 50 day moving average is $4.35 and its 200-day moving average is $3.85. Personalis has a 1 year low of $1.12 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analysts' expectations of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same period last year, the company earned ($0.51) EPS. Analysts forecast that Personalis will post -1.41 EPS for the current year.

Institutional Investors Weigh In On Personalis

A number of hedge funds and other institutional investors have recently bought and sold shares of PSNL. nVerses Capital LLC purchased a new stake in shares of Personalis in the third quarter valued at about $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock valued at $81,000 after buying an additional 4,504 shares in the last quarter. International Assets Investment Management LLC grew its holdings in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after buying an additional 17,082 shares during the last quarter. Quantbot Technologies LP purchased a new position in Personalis during the third quarter worth $210,000. Finally, Barclays PLC raised its holdings in shares of Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company's stock worth $352,000 after acquiring an additional 20,444 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.